Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.41 |
| ▸ | TET3 | O43151 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 10/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRE | P78334 | 2/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9219251 | 1.00 | CYP1A2 (0.45) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL5571470 | 1.00 | CYP1A2 (0.45) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL3471974 | 0.98 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL3471976 | 0.98 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL18342498 | 0.98 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL16240446 | 0.84 | ALOX15 (0.45) | GRIK1SLC1A3SLC1A2SLC1A1GRIK2 | |
| SCHEMBL16240444 | 0.84 | ALOX15 (0.45) | GRIK1SLC1A3SLC1A2SLC1A1GRIK2 | |
| Hydrochloric Acid SCHEMBL3816765 | 0.82 | ALOX15 (0.44) | SLC1A3SLC1A2SLC1A1BLM | |
| SCHEMBL9087014 | 0.81 | MVD (0.33) | — | |
| SCHEMBL28773184 | 0.80 | CYP1A2 (0.42) | CYP1A2TET2KDM4AKDM4CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20230122957-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-3723815-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019115547-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2019-06-20 | — | — | WO | disclosed |
| EP-0708660-B1 | COMPOUNDS USEFUL FOR PREPARING PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RES CAMPAIGN TECH (GB) | 2007-05-09 | — | — | EP | disclosed |
| US-5770731-A | PROTECTING GROUPS, ANTIBODY DIRECTED ENZYME/PRODRUG THERAPY, ANTICARCINOGENIC AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| US-5728868-A | Prodrugs of protein tyrosine kinase inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
| EP-0711177-A1 | IMPROVEMENTS RELATING TO PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| EP-0708660-A1 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995003830-A2 | PRODRUGS OF FARNESYL TRANSFERASE INHIBITORS FOR ADEPT OR VDEPT | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| WO-1995002420-A2 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1995-01-26 | — | — | WO | disclosed |
| US-5382582-A | Methotrexate analogs and methods of using same | CHAN CARCY L (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0581789-A1 | NOVEL 2-SPIROCYCLOPROPYL CEPHALOSPORIN SULFONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | SYNPHAR LABORATORIES INC. (CA) | 1994-02-09 | — | — | EP | disclosed |
| US-5260296-A | Thiophene substituted antitumor antifolates | BIONUMERIK PHARMACEUTICALS, INC. | 1993-11-09 | — | — | US | disclosed |
| WO-1992018474-A2 | NOVEL 2-SPIROCYCLOPROPYL CEPHALOSPORIN SULFONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | SYNPHAR LABORATORIES, INC. (CA) | 1992-10-29 | — | — | WO | disclosed |
| US-5145854-A | 1-formyl-5,8,10-trideazafolates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1992-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122957-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | KLK3, FOLH1, EEA1 | CYP1A2 4483/4885TET2 4845/4885KDM4A 1690/4885 |
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | SSTR3, SLC43A1, SSTR1 | CYP1A2 4635/4885TET2 4126/4885KDM4A 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.